LFTD Partners Inc. (LIFD) Sells Building for $1.5M, Repays Bank Debt

LFTD PARTNERS INC. (LIFD) filed an SEC Form 8-K — Completion of Acquisition or Disposition of Assets. Lifted Made Completes $1.5 Million Sale of Kenosha Building and Repays all Outstanding Bank Debt Following the sale and repayment, LFTD Partners Inc. holds more than $2.4 million in cash KENOSHA, WI, October 1, 2026 -- Lifted Made , a wholly owned subsidiary of LFTD Partners Inc.

H.C. Wainwright reiterated a Buy rating and $25 price target on Ultragenyx (RARE) after its sale of a priority review voucher for $210M. The company's stock is down 52% over the past year. Ultragenyx also received FDA approval for FAYUVI, its gene therapy for Sanfilippo syndrome Type A, marking its second gene therapy approval.

X4 Pharmaceuticals (XFOR) secured a $150M senior secured debt facility from K2 HealthVentures, replacing its previous loan. The initial $80M tranche was used to repay existing debt, with an additional $70M available. The company aims to advance mavorixafor (XOLREMDI) for chronic neutropenia, with Phase 3 trial results expected in 2028. XFOR stock closed at $2.81, up 1.44%.

X4 Pharmaceuticals (XFOR) secured a $150M debt facility with K2 HealthVentures, replacing its prior loan and providing more financial flexibility. The first $80M was funded immediately.

Crescent Energy Company (CRGY) announced a $1B public offering of Class A common stock, with an option for an additional $150M. Proceeds will fund its planned acquisition of Devon Eagle Ford assets or be used for general purposes if the deal is not completed.

X4 Pharmaceuticals (XFOR) secured a $150M loan facility with K2 HealthVentures, receiving $80M initially to repay prior debt. The remaining $70M is subject to approval. Funds support corporate activities, including a potential commercial launch of mavorixafor for chronic neutropenia. XFOR expects Phase 3 trial results in 2028.